EPISODE · Dec 16, 2017 · 26 MIN
A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates
from The Onco'Zine Brief with Peter Hofland · host Peter Hofland
Recorded during CPhI World Wide, October 24 - 27, 2017 in Frankfurt Germany, Peter Hofland and Sonia Portillo interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.
What this episode covers
Recorded during CPhI World Wide, October 24 - 27, 2017 in Frankfurt Germany, Peter Hofland and Sonia Portillo interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.
NOW PLAYING
A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m